Browse our latest Immunology and Inflammation articles

Combining experiments, bioinformatics, and mathematical modelling, we find large heterogeneity in naive T cell clone sizes.

SLAMF6 is an inhibitory checkpoint of T cells, the lack of which leads to better tumor control, suggesting a new immunotherapy target.

A novel IVDD mechanism that involves p16 is demonstrated and theoretical evidence is provided for effective methods to downregulate p16 and so reverse IVDD.

Mycobacterium tuberculosis penetrates the airway mucosa through M cells via the mycobacterial virulence factor EsxA and the host M cell surface receptor scavenger receptor B1.

LXA₄ in lymph nodes is an important resident homeostatic regulator that controls effector T cell functions and egress in the development of adaptive immune responses.

The crystal structure of neutralizing antibody AR3X in complex with HCV E2 glycoprotein reveals unusual features of antibody recognition in which a conserved epitope is recognized by distinct antibody poses.

CFTR modulators have potent innate anti-inflammatory properties that can be measured in clinic, both ex vivo and in vitro, which can be used to predict treatment efficacy.

The thioredoxin-1 (Trx1) system promotes inflammation by positively regulating both NLRP3 inflammasome responses, by detoxifying excessive ROS independently of Txnip and NF-κB binding to target DNA.

High-throughput clonal tracking quantifies intrinsic differences between primary and secondary T cell response.

Immune checkpoint inhibition therapy for cancer paradoxically activates tuberculosis infection, and advanced human cell culture modelling demonstrates excess TNF-α section is the primary driver.